NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BioCardia, Inc. (BCDA) Stock Analysis

BioCardia, Inc. (BCDA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BCDA

$0.98

−$0.06 (−5.54%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCDA with… →

BCDA Key Statistics

As of Oct 21, 2026
Trading
Open
$1.05
Previous Close
$1.04
Day's Range
0.97–1.05
52-Week Range
0.75–1.80
Volume
133.37K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.62
Valuation
Market Cap
$15.74M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.64
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$8.23M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.14M
1-Year Return
−34.07%
Dividend and dates
Avg Volume
257.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BCDA closed at $0.98, −34.07% over 1 year.

BioCardia, Inc. (BCDA) has a market capitalization of $15.74M.

In fiscal 2025, BCDA reported revenue of $0.00.

BCDA Stock Return by Calendar Year

BioCardia, Inc. (BCDA) 10-year return: what $10,000 became

1 year
$10,000 $6,593
−34.07%
5 years
$10,000 $223
−97.77%
10 years
$10,000 $55
−99.45%

If you had invested $10,000 in BioCardia, Inc. (BCDA) 10 years ago, at the close on October 21, 2016, it would have been worth $55 at the close on October 21, 2026: −99.45% in total, −40.55% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.41%
2025−42.66%
2024−77.98%
2023−68.42%
2022+7.73%
2021−43.93%
2020−5.98%
2019−65.93%
2018−48.94%
2017−81.87%
2016 (partial year)+730.77%

As of October 21, 2026.

BCDA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.23M—
2024$58.00K−$7.95M−13,700.0%
2023$477.00K−$11.57M−2,425.8%
2022$1.35M−$11.91M−880.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$8.28M−$8.23M—
2024$58.00K—−$8.00M−$7.95M−13,700.0%
2023$477.00K—−$11.64M−$11.57M−2,425.8%
2022$1.35M—−$11.90M−$11.91M−880.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BioCardia, Inc. (BCDA) at $15.74M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 17.

BCDA last closed at $0.98 on October 21, 2026. That is −$0.06 (−5.54%) against the previous close. Over the past 52 weeks the price has ranged from $0.75 to $1.80. The latest close sits 30.99% above that 52-week low.

Financial Health

In fiscal 2025, BioCardia, Inc. reported revenue of $0.00. Against the prior fiscal year total of $58.00K, that is a change of −100.00%. The same year closed with a net loss of $8.23M. Trailing earnings per share are −0.64.

Across the 4 fiscal years on file, revenue moves from $1.35M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −34.07%. Measured over 10 years, that is −40.55% a year compounded. The reported beta is 0.62. Annualized volatility over the trailing 10 years is 123.05%.

Growth & Income

The record shows no dividend for BCDA.

2026 is still running; the total return is −21.41% year to date. The strongest complete calendar year on file is 2022 at +7.73%; the weakest is 2017 at −81.87%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

BioCardia, Inc. (BCDA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioCardia, Inc. BCDA $15.74M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BioCardia, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BioCardia, Inc.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Visit website →